Global ImmuNotoxins market is expected to grow at a CAGR of 7.8% during the forecast period. Global ImmuNotoxins market is expected to reach US$ 275.60 Mn. by 2029.To know about the Research Methodology :- Request Free Sample Report
Market Overview & Dynamics:
Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that binds specifically to target cells. They are created by chemically conjugating an antibody to a whole protein toxin, devoid of its natural binding domain. Immunotoxins are essentially used in the treatment of various types of cancers and viral infections.DAB389IL2 was the first immunotoxin approved by the Food and Drug Administration, well known as deni-leukin diftitox. Current trends and researches are ongoing on finding proteins that in combination with Immunotoxins have minimal immunogenicity and the most potency for target cell killing.Brentuximab vedotin (Anti-CD30, MMAE) and ado-trastuzumab emtansine (Anti-Her2/neu, maytansine) are approved by the FDA for the treatment of Hodgkin’s lymphoma and HER2 positive metastatic breast cancer, respectively. Prevalence of cancer worldwide is responsible in driving the Immunotoxins market. Cancer remains one of the leading causes of death worldwide. Conventional therapeutic strategies usually offer limited specificity, which results in side effects and toxicity to normal tissues. Hence, the demand for targeted cancer therapy is increasing. Targeting using Immunotoxins can also be achieved through gene delivery and cell-specific expression of a toxin. These are the major advantages of Immunotoxins which augment the market growth. According to GLOBCAN, it is expected that the yearly death toll due to cancer will reach 16 million by 2040. On a global scale, the Immunotoxins market is currently showing significant development. The innovative methods and market study by prominent players are helping in the launch of new improved products are the prime drivers of the Immunotoxins market. In addition, an increase in the adoption of Immunotoxins for non-medical applications, and emerging economies such as China, India, and others, will create new opportunities for the global Immunotoxins market. Challenges associated with the development of Immunotoxins probably may hamper the market growth. Several challenges associated with Immunotoxins development for cancer therapy include immunogenicity, unwanted toxicity, difficulty in production, limited half-life, and resistance may cause hindrance in market growth. Also, higher cost of the research and development and inefficient execution of plan may restraint the market growth for Immunotoxins. However, Future development may include combinations of Immunotoxins with other anticancer therapies in order to overcome problems of tumor penetration, toxicity, and immunogenicity, which will create opportunities for the major players for the development of new advanced products. The report has profiled key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.Global Immunotoxins Market Segment Analysis:
The global Immunotoxins market is segmented based on type and application. On the basis of type segment, various Immunotoxins commonly used are included like, anthrax-based toxins, diphtheria toxin (DT) & DT derivatives, pseudomonas exotoxin, and ribonucleases based Immunotoxins. The diphtheria toxin & its derivatives segment is considered to be the dominant one as the truncated forms of DT have been successfully used to generate recombinant Immunotoxins against cancer. In vitro, these immunotoxins have shown very small IC50s on the order of 10–9–10–14 M, which validates their possible use as targeted therapy. For cells that are not targeted or that do not contain a targeted receptor, DT-based immunotoxins tend to have an IC50 on the order of 10–7 M. Based on the applications, it is diversified into solid tumors and Leukemias. The Leukemias segment is anticipated to dominate the global market as Immunotoxins therapy is largely applied to treating various Leukemias like Hairy Cell Leukemia, Acute Myelogenous Leukemia, etc. The application of immunotoxins in solid tumor treatment encounters some obstacles. Ineffective penetration of immunotoxins into tumor tissues and neutralizing the activity of perfect immunity of patients affected the development of immunotoxins. Emerging new technologies would help us to refine immunotoxin designing to defeat such problems. Among the immunotoxin therapies against solid tumors, treatment of brain tumors has had a promising result because of emerging new drug delivery methods, thereby facilitating immunotoxin penetration.Global Immunotoxins Market Regional Insights:
North America is projected to dominate the global market by holding a revenue share of $xx MN during forecast period. Increasing cancer patient pool in the US is expected to drive the market by creating new opportunities for the development of new advanced technologies. Cancer has a major impact on society in the United States and across the world. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Estimated national expenditures for cancer care in the United States in 2018 were $150.8 billion. In future years, costs are likely to increase as the population ages and more people have cancer. Costs are also likely to increase as new, and often more expensive, treatments are adopted as standards of care. APAC is expected as the fastest growing region during forecast period. Owing to the rapidly increasing geriatric population, modernization in healthcare infrastructure increased healthcare expenditure and increasing government initiatives to spread awareness about new advanced therapies for cancer treatment. The report also helps in understanding Global Immunotoxins Market dynamics, structure by analyzing the market segments and project the Global Immunotoxins Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immunotoxins Market make the report investor’s guide.
Scope of the Global Immunotoxins Market: Inquire before Buying
Global Immunotoxins Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 162.91 Bn. Forecast Period 2023 to 2029 CAGR: 7.8% Market Size in 2029: US $ 275.60 Bn. Segments Covered: by Type Anthrax Based Toxins Diphtheria Toxin (DT) & DT Derivatives Pseudomonas Exotoxin (PE) & PE Derivatives Ribonucleases based Immunotoxins by Application Solid Tumors Leukemias Global Immunotoxins Market, By Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Immunotoxins Market, Key Players:
1. Biotest 2. Celldex Therapeutics 3. Amgen 4. Genmab 5. AREVA Med 6. Bayer HealthCare 7. Neurocrine Biosciences 8. Research Corporation Technologies 9. CuraGen Corporation 10.Genentech 11.Lifescan Inc. 12.Abbott laboratories 13.Acon laboratories 14.Others FAQ 1] What segments are covered in the Global Immunotoxins Market report? Ans. The segments covered in the Global Immunotoxins Market report are based on Type, Application. 2] Which region is expected to hold the highest share in the Global Immunotoxins Market? Ans. North America region is expected to hold the highest share in the Global Immunotoxins Market. 3] What is the market size of the Global Immunotoxins Market by 2029? Ans. The market size of the Global Immunotoxins Market by 2029 is expected to reach US$ 275.60 Mn. 4] What is the forecast period for the Global Immunotoxins Market? Ans. The forecast period for the Global Immunotoxins Market is 2023-2029. 5] What was the market size of the Global Immunotoxins Market in 2022? Ans. The market size of the Global Immunotoxins Market in 2022 was valued at US$ 162.91 Mn..
1. ImmuNotoxins Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. ImmuNotoxins Market: Dynamics 2.1. ImmuNotoxins Market Trends by Region 2.1.1. North America ImmuNotoxins Market Trends 2.1.2. Europe ImmuNotoxins Market Trends 2.1.3. Asia Pacific ImmuNotoxins Market Trends 2.1.4. Middle East and Africa ImmuNotoxins Market Trends 2.1.5. South America ImmuNotoxins Market Trends 2.2. ImmuNotoxins Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America ImmuNotoxins Market Drivers 2.2.1.2. North America ImmuNotoxins Market Restraints 2.2.1.3. North America ImmuNotoxins Market Opportunities 2.2.1.4. North America ImmuNotoxins Market Challenges 2.2.2. Europe 2.2.2.1. Europe ImmuNotoxins Market Drivers 2.2.2.2. Europe ImmuNotoxins Market Restraints 2.2.2.3. Europe ImmuNotoxins Market Opportunities 2.2.2.4. Europe ImmuNotoxins Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific ImmuNotoxins Market Drivers 2.2.3.2. Asia Pacific ImmuNotoxins Market Restraints 2.2.3.3. Asia Pacific ImmuNotoxins Market Opportunities 2.2.3.4. Asia Pacific ImmuNotoxins Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa ImmuNotoxins Market Drivers 2.2.4.2. Middle East and Africa ImmuNotoxins Market Restraints 2.2.4.3. Middle East and Africa ImmuNotoxins Market Opportunities 2.2.4.4. Middle East and Africa ImmuNotoxins Market Challenges 2.2.5. South America 2.2.5.1. South America ImmuNotoxins Market Drivers 2.2.5.2. South America ImmuNotoxins Market Restraints 2.2.5.3. South America ImmuNotoxins Market Opportunities 2.2.5.4. South America ImmuNotoxins Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For ImmuNotoxins Industry 2.8. Analysis of Government Schemes and Initiatives For ImmuNotoxins Industry 2.9. ImmuNotoxins Market Trade Analysis 2.10. The Global Pandemic Impact on ImmuNotoxins Market 3. ImmuNotoxins Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 3.1.1. Anthrax Based Toxins 3.1.2. Diphtheria Toxin (DT) & DT Derivatives 3.1.3. Pseudomonas Exotoxin (PE) & PE Derivatives 3.1.4. Ribonucleases based Immunotoxins 3.2. ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 3.2.1. Solid Tumors 3.2.2. Leukemias 3.3. ImmuNotoxins Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America ImmuNotoxins Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 4.1.1. Anthrax Based Toxins 4.1.2. Diphtheria Toxin (DT) & DT Derivatives 4.1.3. Pseudomonas Exotoxin (PE) & PE Derivatives 4.1.4. Ribonucleases based Immunotoxins 4.2. North America ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 4.2.1. Solid Tumors 4.2.2. Leukemias 4.3. North America ImmuNotoxins Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 4.3.1.1.1. Anthrax Based Toxins 4.3.1.1.2. Diphtheria Toxin (DT) & DT Derivatives 4.3.1.1.3. Pseudomonas Exotoxin (PE) & PE Derivatives 4.3.1.1.4. Ribonucleases based Immunotoxins 4.3.1.2. United States ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 4.3.1.2.1. Solid Tumors 4.3.1.2.2. Leukemias 4.3.2. Canada 4.3.2.1. Canada ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 4.3.2.1.1. Anthrax Based Toxins 4.3.2.1.2. Diphtheria Toxin (DT) & DT Derivatives 4.3.2.1.3. Pseudomonas Exotoxin (PE) & PE Derivatives 4.3.2.1.4. Ribonucleases based Immunotoxins 4.3.2.2. Canada ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 4.3.2.2.1. Solid Tumors 4.3.2.2.2. Leukemias 4.3.3. Mexico 4.3.3.1. Mexico ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 4.3.3.1.1. Anthrax Based Toxins 4.3.3.1.2. Diphtheria Toxin (DT) & DT Derivatives 4.3.3.1.3. Pseudomonas Exotoxin (PE) & PE Derivatives 4.3.3.1.4. Ribonucleases based Immunotoxins 4.3.3.2. Mexico ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 4.3.3.2.1. Solid Tumors 4.3.3.2.2. Leukemias 5. Europe ImmuNotoxins Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.2. Europe ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3. Europe ImmuNotoxins Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.1.2. United Kingdom ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.2. France 5.3.2.1. France ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.2.2. France ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.3. Germany 5.3.3.1. Germany ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.3.2. Germany ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.4. Italy 5.3.4.1. Italy ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.4.2. Italy ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.5. Spain 5.3.5.1. Spain ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.5.2. Spain ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.6.2. Sweden ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.7. Austria 5.3.7.1. Austria ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.7.2. Austria ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 5.3.8.2. Rest of Europe ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6. Asia Pacific ImmuNotoxins Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.2. Asia Pacific ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3. Asia Pacific ImmuNotoxins Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.1.2. China ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.2.2. S Korea ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.3. Japan 6.3.3.1. Japan ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.3.2. Japan ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.4. India 6.3.4.1. India ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.4.2. India ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.5. Australia 6.3.5.1. Australia ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.5.2. Australia ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.6.2. Indonesia ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.7.2. Malaysia ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.8.2. Vietnam ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.9.2. Taiwan ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 6.3.10.2. Rest of Asia Pacific ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 7. Middle East and Africa ImmuNotoxins Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 7.2. Middle East and Africa ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 7.3. Middle East and Africa ImmuNotoxins Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 7.3.1.2. South Africa ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 7.3.2. GCC 7.3.2.1. GCC ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 7.3.2.2. GCC ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 7.3.3.2. Nigeria ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 7.3.4.2. Rest of ME&A ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 8. South America ImmuNotoxins Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 8.2. South America ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 8.3. South America ImmuNotoxins Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 8.3.1.2. Brazil ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 8.3.2.2. Argentina ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America ImmuNotoxins Market Size and Forecast, by Type (2022-2029) 8.3.3.2. Rest Of South America ImmuNotoxins Market Size and Forecast, by Application (2022-2029) 9. Global ImmuNotoxins Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading ImmuNotoxins Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Biotest 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Celldex Therapeutics 10.3. Amgen 10.4. Genmab 10.5. AREVA Med 10.6. Bayer HealthCare 10.7. Neurocrine Biosciences 10.8. Research Corporation Technologies 10.9. CuraGen Corporation 10.10. Genentech 10.11. Lifescan Inc. 10.12. Abbott laboratories 10.13. Acon laboratories 10.14. Others 11. Key Findings 12. Industry Recommendations 13. ImmuNotoxins Market: Research Methodology 14. Terms and Glossary